(NASDAQ)
22.57
+0.74   (+3.14%)
 
Volume (24h) Market Cap. Day Range 52w Range
141.62K 1.02B 21.97 - 23.04 6.01 - 28.09
Jan-21-21 07:00AM Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian CancerPR Newswire
Jan-05-21 07:00AM Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare ConferencePR Newswire
Dec-11-20 04:01AM Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional SharesPR Newswire
Dec-08-20 09:10AM Sutro Biopharma Announces Pricing of $126.0 Million Public OfferingPR Newswire
Dec-07-20 04:00AM Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common StockPR Newswire
10:00AM Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual MeetingPR Newswire
Dec-04-20 06:22AM Why Sutro Biopharma Blasted 33% Higher on FridayMotley Fool
12:59PM Why BioCryst, Moderna And More Are Moving TodayBenzinga
Dec-04-20 07:43AM The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOsBenzinga
Dec-03-20 04:30AM Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian CancerPR Newswire
01:09AM Why Sutro, Lumos And More Health Care Stocks Are Moving TodayBenzinga
Dec-01-20 07:00AM Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of DirectorsPR Newswire
Nov-24-20 07:00AM Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian CancerPR Newswire
Nov-18-20 07:00AM Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor RelationsPR Newswire
Nov-09-20 09:49AM Sutro Biopharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next YearSimply Wall St.
Nov-05-20 07:00AM Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and DevelopmentsPR Newswire
Nov-03-20 01:33AM If You Had Bought Sutro Biopharma (NASDAQ:STRO) Stock A Year Ago, You Could Pocket A 27% Gain TodaySimply Wall St.
Oct-12-20 12:10PM Hedge Funds Are Dipping Their Toes Into Sutro Biopharma, Inc. (STRO)Insider Monkey
Sep-21-20 07:00AM Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADCPR Newswire
Sep-10-20 07:20AM The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy TrialBenzinga
Sep-09-20 04:01AM Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global MeetingPR Newswire
Sep-04-20 07:27AM Sutro Biopharma, Inc. (NASDAQ:STRO) Insiders Increased Their HoldingsSimply Wall St.
Sep-03-20 04:27AM Macy's, Carnival: 5 Big Stock Gainers for ThursdayTheStreet.com
07:55AM The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From NovavaxBenzinga
Sep-03-20 07:00AM Sutro Biopharma to Present at Two Upcoming Investor ConferencesPR Newswire
Sep-02-20 04:12AM Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global MeetingPR Newswire
10:22AM Well Fargo Says These 2 Stocks Could Rally Over 70% From Current LevelsTipRanks
Aug-25-20 07:00AM Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid TumorsPR Newswire
Aug-11-20 07:00AM Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of ManufacturingPR Newswire
Aug-10-20 05:00AM Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferencePR Newswire
Aug-06-20 12:15PM Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue EstimatesZacks
07:00AM Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and DevelopmentsPR Newswire
Aug-05-20 12:30PM Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should KnowZacks
Jun-30-20 11:06AM Were Hedge Funds Right About Souring On Sutro Biopharma, Inc. (STRO)?Insider Monkey
Jun-22-20 07:00AM Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor ImmunityPR Newswire
Jun-11-20 02:34AM Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO)Business Wire
Jun-09-20 07:00AM Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020PR Newswire
Jun-08-20 06:06AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STROGlobeNewswire
01:25AM Got $1,000? Buy These 4 Cancer StocksMotley Fool
May-21-20 07:15AM Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and ControllerPR Newswire
07:00AM Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MDPR Newswire
May-14-20 04:01AM Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesPR Newswire
May-12-20 04:45AM STRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sutro Biopharma, Inc. and Encourages Investors to Contact the FirmACCESSWIRE
May-11-20 11:55AM Sutro Biopharma Announces Pricing of $85.3 Million Public OfferingPR Newswire
04:15AM Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and DevelopmentsPR Newswire
Apr-27-20 12:01PM Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian CancerPR Newswire
Apr-20-20 04:35AM Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug ConjugatePR Newswire
Apr-13-20 05:00AM Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020PR Newswire
11:01AM Will Sutro Biopharma Continue to Surge Higher?Zacks
Mar-26-20 09:20AM $110M injection powers up Peninsula vaccine maker — but not for COVID-19American City Business Journals
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Cap:    |  Volume (24h):